Non-Luer Butterfly Needle With One-way Valve for the Epidural Blood Patch: Does it Alter Blood Clotting?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-01

Study Completion Date

2017-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Department of Health recommends using equipment which prevents wrong route drug administration. However, the epidural blood patch requires equipment that connects to the intravenous and epidural route. To comply with these recommendations a non-Luer butterfly needle with one-way valve has been produced. The one-way valve and length of tubing has the potential to activate the clotting cascade. This could reduce the time clinicians have to utilise the blood in the syringe. Also any alteration in clotting could affect the therapeutic value of the epidural blood patch. The primary objective of this research was to determine if phlebotomy using this new 21G needle altered blood clotting, determined by thromboelastograph analysis, compared to a standard 21G hypodermic needle.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravascular Injection Rate During Lumbar Transforaminal Epidural Block Using Bent or Straight Needles

NCT05849324

Analgesia, Epidural

UNKNOWN NA

Assessment of Ultrasound-guided Inserted Peripheral Intravenous Catheter

NCT01602133

Venous Puncture

UNKNOWN NA

Ultrasound-guided Subclavian Vein Catheterisation With a Needle Guide

NCT05513378

Complications; Catheter, Mechanical Catheterization, Central Venous

COMPLETED NA

Upper Limb Thrombosis Associated With Midline Catheter

NCT03036540

Venous Thrombosis Deep (Limbs)

UNKNOWN

Evaluation of the Occurrence of Acute Complications Caused by a Central Venous Catheter Placement

NCT01405534

Anesthesia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ethical approval was gained from the Health Research Authority (North West - Greater Manchester South Research Ethics Committee, REC Reference Number: 16/NW/0570). After informed consent, we enrolled participants

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-Dural Puncture Headache Low Pressure Headache

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

butterfly needle with valve

thromboelastography

Group Type OTHER

Thromboelastography

Intervention Type DIAGNOSTIC_TEST

paired TEG analysis undertaken from participants with the two different needles

Standard hypodermic needle

thromboelastography

Group Type OTHER

Thromboelastography

Intervention Type DIAGNOSTIC_TEST

paired TEG analysis undertaken from participants with the two different needles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thromboelastography

paired TEG analysis undertaken from participants with the two different needles

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant is willing and able to give informed consent for participation in the study.
* Male or Female.
* Aged 18 years or above.
* Within first 2 days postnatal for postnatal group
* Healthy participants must be in good health.
* Able (in the Investigators opinion) and willing to comply with all study requirements.
* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.

Exclusion Criteria

* Any medical condition
* In postnatal group, women with haemorrhage greater than 1L
* In postnatal group, less than 12 hours post prophylactic dalteparin
* Any clotting abnormality
* On any medication including herbal medication (vitamins taken during pregnancy are acceptable)
* Age less than 18 years at recruitment
* Adults who are not capable of giving valid consent
* Adults with learning disabilities/ difficulties
* Adults in emergency situations
* Unable to speak or read English
* Prisoners
* Adults unable to consent for themselves
* Any person considered to have a particularly dependent relationship with investigators
* Any others deemed to belong to a vulnerable group.
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
* Participants who have participated in another research study involving an investigational product in the past 12 weeks

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes